European Commission grants orphan designation to Vanda’s imsidolimab for generalised pustular psoriasis

The designation provides regulatory development incentives for Vanda’s IL-36 receptor inhibitor in the EU and follows orphan status for the investigational therapy in the US and Japan.

The European Commission has granted orphan designation to Vanda Pharmaceuticals’ imsidolimab for the treatment of generalised pustular psoriasis (GPP), following a positive opinion from the EMA’s Committee for Orphan Medicinal Products. The designation is the first EU orphan recognition for a GPP treatment and provides development incentives, but it does not constitute marketing authorisation.

Field	Content
Alert Type	Industry Update
Topic	Orphan designation; Regulatory development
Organisation(s)	Vanda Pharmaceuticals; European Commission; European Medicines Agency (EMA)
Affected Stakeholders	Vanda Pharmaceuticals; dermatologists; GPP researchers; patients with generalised pustular psoriasis
Therapy Area(s)	Dermatology; Rare disease; Generalised pustular psoriasis
Geography	European Union
What Happened	On 24 August 2026, Vanda announced that the European Commission had granted orphan designation to imsidolimab for GPP, based on a positive opinion from the EMA’s Committee for Orphan Medicinal Products. Imsidolimab is an investigational humanised IgG4 monoclonal antibody targeting the IL-36 receptor. According to Vanda, this is the first time the European Commission has granted orphan designation to a medicine for GPP. The designation recognises the programme under the EU orphan-medicines framework but does not constitute approval or marketing authorisation. (PR Newswire)
Why It Matters	EU orphan designation can provide incentives including protocol assistance, reduced regulatory fees and, if the medicine is subsequently approved and continues to meet the applicable criteria, market-exclusivity benefits. For Vanda, the decision adds European orphan status to designations already granted in the US and Japan as it pursues development of imsidolimab across major markets. (BioPharm International)
Supporting Context	GPP is a rare, potentially life-threatening inflammatory skin disease characterised by widespread pustular eruptions and systemic inflammation and associated with dysregulation of IL-36 signalling. Imsidolimab is designed to inhibit IL-36 receptor signalling and has been evaluated in the Phase III GEMINI-1 study. (PR Newswire)
Who Is Most Affected	Vanda is most directly affected because the designation provides regulatory incentives as it advances imsidolimab in Europe. Dermatologists and patients with GPP are the relevant clinical stakeholders, although imsidolimab remains investigational and the designation does not make it available for routine treatment.
Industry Impact	The decision formally recognises imsidolimab within the EU orphan-medicines framework and may support Vanda’s European development strategy. Its impact on GPP treatment will depend on subsequent regulatory submissions, assessment and any eventual marketing authorisation.
Key Takeaway	European orphan designation gives Vanda additional regulatory support for imsidolimab’s development in GPP but should not be confused with approval of the medicine.
What to Watch	Imsidolimab’s US BLA is currently under FDA review with a target action date of 12 December 2026, while further European regulatory steps will determine whether the programme progresses towards an EU marketing authorisation application. (BioPharm International)
Primary Source	Vanda Pharmaceuticals – European Commission orphan designation announcement
Relevant Date	24 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com